Advanced Chemical Industries Limited

2nd Quarter ended Report 2021-2022 for the six months period ended on 31 December 2021

Advanced Chemical Industries Limited

Statement of financial position Unaudited

	Unaudited		
		Fi	gures in '000' Taka
		As at	As at
	Note	31 December 2021	30 June 2021
Assets			
Property, plant and equipment	2	13,140,739	12,960,524
Right-of-use assets	2	422,075	506,003
Investments	3	3,090,864	3,139,924
Intangible assets	5	2,375	2,807
Biological assets		18,662	17,778
Deferred tax assets		186,049	88,781
Non-current assets	an a	16,860,765	16,715,817
T			
Inventories	4	6,931,926	6,773,320
Trade receivables	5	2,955,330	2,910,514
Other receivables		1,075,893	543,149
Inter-company receivables	6	24,463,486	20,142,239
Advances, deposits and prepayments	7	727,064	847,271
Cash and cash equivalents		1,946,243	1,672,220
Current assets		38,099,943	32,888,713
Total assets	х Полого и полого полог	54,960,707	49,604,530
Equity			
Share capital		725,768	631,103
Share premium		402,310	402,310
Reserves		5,119,658	5,165,968
Retained earnings		13,578,787	12,693,655
Total equity		19,826,523	18,893,035
Liabilities			
Employee benefits	8	1,285,203	1,123,745
Long term borrowings	9	1,190,003	1,044,720
Non-current portion of lease liabilities		305,788	378,647
Non-current liabilities		2,780,994	2,547,112
Bank overdraft		4,175,612	1,681,373
Loans and borrowings	10	18,445,108	17,068,609
Current portion of lease liabilities	10	153,030	175,644
Trade payables		1,418,398	1,371,347
Inter-company payables	11	3,409,099	4,269,065
Other payables	12	3,573,890	3,071,296
Unclaimed/unpaid dividend account	12	486,094	118,208
Current tax liabilities		691,959	408,838
Current liabilities	<u>ระสารแรงสารผู้สายสาวการเราะสาวสา</u> หยุ่งการเราะสาวการเราะสา	32,353,190	28,164,381
Total liabilities		35,134,184	30,711,494
Total equity and liabilities		54,960,707	49,604,530

Net asset value (NAV) per share (in Taka)

lm la Director

Managing Director

Chief Financial Officer

L

273.18 260.32 /dompany Secretary

7

Advanced Chemical Industries Limited Statement of profit or loss Unaudited

				Figu	res in '000' Taka		
¥		For the half year from		For the 2nd Quarter from			
	Note	July 2021 to December 2021	July 2020 to December 2020	October 2021 to December 2021	October 2020 to December 2020		
Revenue	13	14,828,347	13,594,216	7,189,359	6,774,685		
Cost of sales	14	(8,305,688)	(7,493,998)	(4,081,276)	(3,792,822)		
Gross profit		6,522,659	6,100,218	3,108,082	2,981,863		
Administrative, selling and distribution expenses	15	(4,820,531)	(4,411,231)	(2,401,072)	(2,173,388)		
Other income		466,111	464,535	436,866	455,341		
Operating profit		2,168,239	2,153,522	1,143,876	1,263,816		
Net finance costs		(202,547)	(180,458)	(108,537)	(59,251)		
Profit before contribution to WPPF		1,965,692	1,973,063	1,035,338	1,204,566		
Contribution to WPPF		(98,285)	(98,653)	(51,767)	(60,228)		
Profit before tax		1,867,407	1,874,410	983,572	1,144,337		
Income tax expense		(477,393)	(486,782)	(238,257)	(277,574)		
Profit after tax		1,390,014	1,387,628	745,315	866,764		

Earnings per share Basic and diluted earnings per share (EPS) (in Taka)

19.15

10.27

19.12

11.94

Managing Director

Director

Chief Financial Officer

Impany Secretary

	For the ha	lf year from	Figures in '000' Ta For the 2nd Quarter from			
	July 2021 to December 2021	July 2020 to December 2020	October 2021 to December 2021	October 2020 to December 2020		
Profit after tax	1,390,014	1,387,628	745,315	866,764		
Other comprehensive income:						
Change in fair value of FVOCI financial assets	(51,455)	25,563	(26,953)	(2,228)		
Income tax on FVOCI financial assets	5,146	(2,556)	2,696	223		
Other comprehensive income, net of tax	(46,309)	23,007	(24,257)	(2,005)		
Total comprehensive income	1,343,705	1,410,635	721,058	864,759		

Advanced Chemical Industries Limited Statement of profit or loss and other comprehensive income Unaudited

Advanced Chemical Industries Limited Statement of changes in equity Unaudited

Figures in '000' Taka

				For th	e half year from	July 2021 to Dec	ember 2021
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2021	631,103	402,310	1,671	453,052	4,711,245	12,693,655	18,893,035
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,390,014	1,390,014
Other comprehensive income-net of tax	-	-	-	(46,309)	-	-	(46,309)
Total comprehensive income	-	-	-	(46,309)	-	1,390,014	1,343,705
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend	94,665	-	-	-	-	(94,665)	-
Cash dividend	-	-	-	-	-	(410,217)	(410,217)
Total transactions with owners of the Company	94,665	-	-	-	-	(504,882)	(410,217)
Balance at 31 December 2021	725,768	402,310	1,671	406,742	4,711,245	13,578,787	19,826,523
	Share capital	Share premium	Capital reserve	For th FVOCI reserve	e half year from Revaluation surplus	July 2020 to Dec Retained earnings	cember 2020 Total equity
Balance at 1 July 2020	573,730	402,310	1,671	434,656	3,075,541	10,933,326	15,421,234
Total comprehensive income							

Balance at 31 December 2020	631,103	402,310	1,671	457,663	3,075,541	11,804,600	16,372,887
Total transactions with owners of the Company	57,373	-	-	-	-	(516,357)	(458,984)
Cash dividend	-	-	-	-	-	(458,984)	(458,984)
Stock dividend	57,373	-	-	-	-	(57,373)	-
Share premium	-	-	-	-	-	-	-
Transaction with owners of the Company							
Total comprehensive income	-	-	-	23,007	-	1,387,628	1,410,635
Other comprehensive income-net of tax	-	-	-	23,007	-	-	23,007
Profit after tax	-	-	-	-	-	1,387,628	1,387,628
l otal comprenensive income							

Advanced Chemical Industries Limited Statement of cash flows

Unaudited	

	F	figures in '000' Taka
	For the ha	lf year from
	July 2021	July 2020
	to	to
	December 2021	December 2020
Cash flows from operating activities		
Cash receipts from customers and others	14,638,073	13,406,196
Cash paid to suppliers and employees	(12,166,004)	(11,553,855)
Cash generated from operating activities	2,472,069	1,852,341
Paid to WPPF	(11,473)	(12,378)
Finance costs paid	(197,483)	(12,576) (155,676)
Income tax paid	(286,396)	(135,676) (270,237)
income tax parti	(495,352)	(438,291)
Net cash from / (used in) operating activities*	16 1,976,717	1,414,050
Tet cash from / (used in) operating activities	10 1,970,717	1,414,030
Cash flows from investing activities		
Acquisition of property, plant and equipment	(77,225)	(70,883)
Payments for capital work in progress	(334,333)	(505,314)
Sale proceeds from property, plant and equipment	2,713	1,255
Purchase of biological assets	(936)	(2,941)
Dividend received	-	394,595
Investment	(2,395)	(90,000)
Net cash from / (used in) investing activities	(412,177)	(273,287)
Cash flows from financing activities		
Inter-company debts received/(paid)	(5,181,213)	(4,049,915)
Dividend paid	(42,330)	(51,534)
Payment for lease liabilities	(91,251)	(77,747)
Short-term bank loan received/(paid)	1,343,962	2,073,162
Long-term bank loan received/(paid)	177,820	310,798
Net cash from / (used in) financing activities	(3,793,012)	(1,795,236)
Net increase / (decrease) in cash and cash equivalents	(2,228,472)	(654,472)
Opening cash and cash equivalents	(9,153)	(1,715,137)
Effect of movements in exchange rates on cash held	8,256	-
Closing cash and cash equivalents	(2,229,370)	(2,369,608)
Closing balance represents		
Cash and cash equivalents	1,946,243	1,506,240
Bank overdraft	(4,175,612)	(3,875,848)
	(2,229,370)	(2,369,608)
Net operating cash flows per share (NOCFPS) (in Taka)) 27.24	19.48

*See Note 16 for reconciliation of net operating cash flow.

Advanced Chemical Industries Limited Consolidated statement of financial position Unaudited

		Fi	gures in '000' Taka
		As at	As at
	Note	31 December 2021	30 June 2021
Assets			
Property, plant and equipment	2 (a)	29,815,643	29,821,715
Right-of-use assets		1,355,175	1,497,953
Equity-accounted investees		1,794,673	1,927,913
Other investments		775,642	810,606
Intangible assets		83,490	93,940
Biological assets		18,662	17,778
Deferred tax assets		670,381	448,005
Non-current assets		34,513,666	34,617,909
Tanan ta si a	4 ()	10 105 220	17 240 040
Inventories	4 (a)	18,195,328	17,349,949
Trade receivables	5 (a)	13,040,055	12,015,538
Other receivables		1,386,765	815,433
Inter-company receivables	6 (a)	9,695	9,586
Advances, deposits and prepayments	7 (a)	2,129,305	2,300,942
Short term investments		1,184,578	1,158,369
Cash and cash equivalents		3,724,013	3,831,929
Current assets		39,669,739	37,481,746
Total assets		74,183,405	72,099,655
Equity			
Share capital		725,768	631,103
Share premium		1,182,924	928,707
Reserves		7,012,283	7,084,649
Retained earnings		1,286,400	1,620,385
Equity attributable to the owners of the Company		10,207,375	10,264,844
Non-controlling interest		1,787,551	838,207
Total equity		11,994,926	11,103,051
Liabilities			
Employee benefits	8 (a)	1,677,567	1,462,875
Long term borrowings	9 (a)	7,420,555	7,843,747
Non-current portion of lease liabilities	5 (u)	1,035,266	1,161,243
Non-current liabilities		10,133,388	10,467,865
Bank overdraft		6,025,131	3,543,944
Loans and borrowings	10 (a)	32,401,024	34,516,421
Current portion of lease liabilities	()	411,623	434,023
Trade payables		5,296,948	4,540,657
Other payables	12 (a)	6,800,713	7,303,909
Unclaimed/unpaid dividend account	12 (u)	625,910	131,177
Current tax liabilities		493,742	58,608
Current liabilities		52,055,091	50,528,739
Total liabilities		62,188,479	60,996,604
Total equity and liabilities		74,183,405	72,099,655
Not assot value (NAV) nor share (in Take)	19	140.64	1/1/2

Net asset value (NAV) per share (in Taka)

6

18

¢ mpany Secretary

141.43

Managing Director

Director

Chief Financial Officer

140.64

Advanced Chemical Industries Limited Consolidated statement of profit or loss Unaudited

				Figu	res in '000' Taka
		For the ha	f year from	For the 2nd	Quarter from
	Note	July 2021 to December 2021	July 2020 to December 2020	October 2021 to December 2021	October 2020 to December 2020
Revenue	12 (a)	45 919 640	27 279 229	04.044.055	10 1 1 2 100
Cost of sales	13 (a)	45,818,649	37,378,330	24,264,977	19,146,438
	14 (a)	(33,211,353)	(26,679,053)	(17,795,094)	(13,708,727)
Gross profit		12,607,296	10,699,277	6,469,883	5,437,711
Administrative, selling and distribution expenses	15 (a)	(9,279,355)	(8,182,733)	(4,773,832)	(4,078,598)
Other income / (loss)		157,159	190,359	81,884	97,131
Operating profit		3,485,101	2,706,902	1,777,935	1,456,244
Share of the profit of equity accounted investees		214,349	251,665	134,405	130,718
Net finance costs		(1,832,473)	(1,793,654)	(947,931)	(870,342)
Profit before contribution to WPPF		1,866,977	1,164,912	964,409	716,620
Contribution to WPPF		(184,715)	(153,835)	(101,132)	(95,436)
Profit before tax		1,682,261	1,011,077	863,277	621,184
Income tax expense		(1,072,489)	(851,076)	(554,790)	(501,497)
Profit after tax		609,772	160,000	308,487	119,687
Profit attributable to:					e.
Equity holders of the company		400,235	201,259	152.082	104,192
Non-controlling interests		209,537	(41,259)	156,405	15,494
Profit after tax		609,772	160,000	308,487	119,687

Earnings per share

Basic and diluted earnings per share (EPS) (in Taka)

5.51

2.77

2.10 1.44

Managing Director

Director

18

Achin

Company Secretary

Chief Financial Officer

7

	For the half	year from	Figures in '000' Taka For the 2nd Quarter from			
	July 2021 to December 2021	July 2020 to December 2020	October 2021 to December 2021	October 2020 to December 2020		
Profit after tax	609,772	160,000	308,487	119,687		
Other comprehensive income:						
Foreign operations - foreign currency translation differences	(23,034)	(233)	(18,231)	(2,439)		
Change in fair value of FVOCI financial assets	(51,748)	26,077	(28,039)	(2,079)		
Income tax on other comprehensive income	5,175	(2,608)	2,804	208		
Other comprehensive income, net of tax	(69,607)	23,237	(43,466)	(4,310)		
Total comprehensive income	540,165	183,237	265,021	115,376		
Total comprehensive income attributable to:						
Equity holders of the Company						
Profit after tax	400,235	201,259	152,082	104,192		
Other comprehensive income	(67,835) 332,400	23,220 224,479	(41,876) 110,206	(4,130) 100,062		
Non-controlling interest						
Profit after tax	209,537	(41,259)	156,405	15,494		
Other comprehensive income	(1,772)	17	(1,590)	(180)		
	207,764	(41,242)	154,815	15,314		
Total comprehensive income	540,165	183,237	265,021	115,376		

Advanced Chemical Industries Limited Consolidated statement of profit or loss and other comprehensive income Unaudited

Advanced Chemical Industries Limited Consolidated Statement of changes in equity Unaudited

Figures in '000' Taka

For the half year from July 2021 to December 2021

		Attributable to owners of the Company								
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2021	631,103	928,707	1,671	(1,397)	452,007	6,632,367	1,620,385	10,264,844	838,207	11,103,051
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	400,235	400,235	209,537	609,772
Other comprehensive income-net of tax	-		-	(21,407)	(46,428)	-	-	(67,835)	(1,772)	(69,607)
Total comprehensive income	-	-	-	(21,407)	(46,428)	-	400,235	332,400	207,764	540,165
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	94,665	-	-	-	-	-	(94,665)	-	-	-
Cash dividend	-	-	-	-	-	-	(410,217)	(410,217)	(62,802)	(473,018)
Effect of issuing new shares to Bangladesh Managed Account C.V. (a										
limited partnership of FMO) by ACI Motors Ltd.	-	254,217	-	-	10	(4,540)	(229,338)	20,348	648,826	669,173
Capital contribution by non-controlling interest (BMA C.V.)	-	-	-	-	-	-	-	-	155,556	155,556
Total transactions with owners of the Company	94,665	254,217	-	-	10	(4,540)	(734,220)	(389,869)	741,579	351,711
Balance at 31 December 2021	725,768	1,182,924	1,671	(22,804)	405,589	6,627,827	1,286,400	10,207,375	1,787,551	11,994,926

For the half year from July 2020 to December 2020

		Attributable to owners of the Company							•	
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2020	573,730	402,310	1,671	(1,397)	433,047	4,277,934	2,211,343	7,898,638	(608,661)	7,289,977
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	201,259	201,259	(41,259)	160,000
Other comprehensive income-net of tax	-	-	-	(216)	23,343	-	-	23,126	110	23,237
Total comprehensive income	-	-	-	(216)	23,343	-	201,259	224,385	(41,148)	183,237
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	57,373	-	-	-	-	-	(57,373)	-	-	-
Cash dividend	-	-	-	-	-	-	(458,984)	(458,984)	(41,868)	(500,851)
Effect of issuing new shares to Bangladesh Managed Account C.V. (a limited partnership of FMO) by ACI Motors Ltd.	-	525,048	-	-	-	-	(298,367)	226,681	769,564	996,245
Capital contribution by non-controlling interest (BMA C.V.)	-	-	-	-	-	-	-	-	233,333	233,333
Total transactions with owners of the Company	57,373	525,048	-	-	-	-	(814,723)	(232,302)	961,029	728,727
Balance at 31 December 2020	631,103	927,358	1,671	(1,613)	456,389	4,277,934	1,597,879	7,890,721	311,219	8,201,942

Advanced Chemical Industries Limited Consolidated statement of cash flows Unaudited

		Fig	ıres in '000' Taka
		For the half	f year from
		July 2021	July 2020
		to	to
		December 2021	December 2020
Cash flows from operating activities			
Cash receipts from customers and others		44,719,102	36,974,310
Cash paid to suppliers and employees		(41,803,118)	(36,624,960)
Cash generated from operating activities		2,915,983	349,350
Paid to WPPF		(55,168)	(42,647)
Finance costs paid		(1,606,892)	(1,474,313)
Income tax paid		(847,071)	(758,897)
^		(2,509,132)	(2,275,857)
Net cash from / (used in) operating activities *	16 (a)	406,852	(1,926,507)
Cash flows from investing activities			
Acquisition of property, plant and equipment		(136,977)	(265,487)
Payments for capital work in progress		(621,552)	(704,316)
Sale proceeds from property, plant and equipment		2,713	1,255
Purchase of biological assets		(936)	(2,941)
Dividend received		-	394,595
Short term investments		(26,208)	(57,755)
Long term investments		(15,393)	(91,876)
Net cash from / (used in) investing activities		(798,353)	(726,524)
Cash flows from financing activities			
Inter-company debts received/(paid)		(108)	(63)
Dividend paid		(42,330)	(51,534)
Payment for lease liabilities		(228,211)	(208,659)
Dividend paid to non-controlling interest		(8,154)	(88)
Equity investment received by ACI Motors Limited		824,729	1,229,579
Short-term bank loan received/(paid)		(2,815,997)	3,915,877
Long-term bank loan received/(paid)		63,346	(1,254,102)
Net cash from / (used in) financing activities		(2,206,725)	3,631,009
Net increase / (decrease) in cash and cash equivalents		(2,598,226)	977,978
Opening cash and cash equivalents		287,985	(2,627,972)
Effect of movements in exchange rates on cash held		9,124	(721)
Closing cash and cash equivalents		(2,301,118)	(1,650,715)
Closing balance represents			
Cash and cash equivalents		3,724,013	3,768,161
Bank overdraft		(6,025,131)	(5,418,876)
		(2,301,118)	(1,650,715)
Net operating cash flows per share (NOCFPS) (in Taka)	18	5.61	(26.54)

*See Note 16(a) for reconciliation of consolidated net operating cash flow.

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2020 to 30 June 2021. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

		Fig	ures in '000' Taka
2	Property, plant and equipment	31 December 2021	30 June 2021
		Taka	Taka
	Opening balance	15,407,109	12,626,796
	· · ·	420,057	2,840,675
		(7,655)	(60,362)
	- ·	(2,678,772)	(2,446,585)
	Closing balance	13,140,739	12,960,524
2 (a)	Consolidated property, plant and equipment		
	Opening balance	36,936,223	32,255,436
	Additions and revaluation	765,951	4,750,379
	Disposals and adjustments	(9,071)	(65,066)
	- ·	(7,877,459)	(7,119,033)
	Closing balance	29,815,643	29,821,715
3	Investments		
	Investment in subsidiaries	1,751,736	1,751,736
	Investment in joint ventures	510,000	510,000
	Investment in associates	548,794	546,398
	Investment in shares	483,390	534,846
	Investment in FDR/ other deposits	70,544	70,544
	 Consolidated property, plant and equipment Opening balance Additions and revaluation Disposals and adjustments Accumulated depreciation Closing balance Investments Investment in subsidiaries Investment in joint ventures Investment in associates Investment in shares 	(273,600)	(273,600)
		3,090,864	3,139,924
4	Inventories		
	Raw materials	2,489,439	2,461,746
	Packing materials	636,723	687,806
	Work-in-process	265,864	304,842
	*	3,571,625	3,231,157
	Goods in transit	430,196	447,602
	Stores and spares	94,643	99,111
	-	(556,564)	(458,945)
		6,931,926	6,773,320

		Figu 31 December 2021 Taka	ures in '000' Taka 30 June 2021 Taka
4 (a)	Consolidated inventories	Turu	I uKu
	Raw materials	4,876,600	4,707,203
	Packing materials	723,095	773,367
	Work-in-process	528,016	540,242
	Finished goods	10,879,226	10,092,334
	Goods in transit	1,734,137	1,703,227
	Stores & spares	258,803	257,385
	Allowance for inventory	(804,549)	(723,808)
		18,195,328	17,349,949
5	Trade receivables		
	Debts due over six months	1,851,683	2,104,043
	Debts due below six months	2,017,419	1,492,357
	Provision for doubtful debts	(913,772)	(685,886)
		2,955,330	2,910,514
5 (a)	Consolidated trade receivables		
	Debts due over six months	3,961,425	4,139,826
	Debts due below six months	10,642,111	9,180,570
	Provision for doubtful debts	(1,563,481)	(1,304,858)
		13,040,055	12,015,538
6	Inter-company receivables		
	ACI Logistics Limited	7,606,319	5,968,826
	ACI HealthCare Limited	7,270,801	6,131,061
	ACI Foods Limited	3,174,387	2,680,268
	Premiaflex Plastics Limited	4,119,109	2,802,198
	ACI Formulations Limited	-	346,312
	ACI Biotech Limited	918,834	884,172
	ACI Agrolink Limited	602,832	582,493
	Infolytx Bangladesh Limited	538,573	447,765
	ACI Chemicals Limited	222,311	211,884
	Asian Consumer Care (Pvt.) Limited	7,894	7,894
	ACI Godrej Agrovet (Pvt.) Limited	930	930
	Tetley ACI (Bangladesh) Limited	841	580
	Stochastic Logic Limited	-	152
	Computer Technology Limited	30	30
	Creative Communication Limited	-	19,352
	ACI Marine and Riverine Technologies Limited ACI Edible Oils Limited	626	- 58,323
		24,463,486	20,142,239

		Figu	ıres in '000' Taka	
	Computer Technology Limited Tetley ACI (Bangladesh) Limited Asian Consumer Care (Pvt.) Limited ACI Godrej Agrovet (Pvt.) Limited Stochastic Logic Limited Advances, deposits & prepayments Advances to staff, suppliers and others VAT current account Deposits Prepayments 7 (a) Consolidated advances, deposits & prepayments Advances to staff, suppliers and others VAT current account Advance for capital expenditure Deposits Prepayments 8 Employee benefits Staff gratuity provision Other long term employee benefits	31 December 2021 Taka	30 June 2021 Taka	
6 (a)	Consolidated inter-company receivables			
	Computer Technology Limited	30	30	
	Tetley ACI (Bangladesh) Limited	841	580	
	Asian Consumer Care (Pvt.) Limited	7,894	7,894	
	ACI Godrej Agrovet (Pvt.) Limited	930	930	
	Stochastic Logic Limited	-	152	
		9,695	9,586	
7	Advances, deposits & prepayments			
	Advances to staff, suppliers and others	181,992	205,689	
		209,948	361,723	
		228,404	239,115	
	-	106,720	40,743	
		727,064	847,271	
7 (a)	Consolidated advances, deposits & prepayments			
	Advances to staff, suppliers and others	899,908	852,166	
	VAT current account	438,630	767,475	
	Advance for capital expenditure	-	733	
	Deposits	419,154	427,409	
	Prepayments	371,613	253,159	
		2,129,305	2,300,942	
8	Employee benefits			
	Staff gratuity provision	1,051,440	920,330	
	Other long term employee benefits	233,763	203,415	
		1,285,203	1,123,745	
8 (a)	Consolidated employee benefits			
	Staff gratuity provision	1,354,244	1,181,776	
	- · · ·	323,323	281,099	
		1,677,567	1,462,875	

	Long term borrowings Long term bank loans Consolidated long term borrowings Long term bank loans Loans and borrowings - short term Short term loan Current portion of long term loan Current portion of long term loan Current portion of long term loan Inter company payables ACI Marine and Riverine Technologies Limited ACI Motors Limited	Fig 31 December 2021 Taka	ures in '000' Taka 30 June 2021 Taka	
9	Long term borrowings			
	Long term bank loans	1,190,003	1,044,720 1,044,720	
9 (a)	Consolidated long term borrowings			
	Long term bank loans	7,420,555	7,843,747	
10	Loans and borrowings - short term	1,120,000	.,	
		18,238,854 206,254	16,894,892 173,718	
10 (a)	Consolidated loans and borrowings - short term	18,445,108	17,068,609	
		29,503,847 2,897,177 32,401,024	32,274,988 2,241,433 34,516,421	
11	Inter company payables			
	ACI Motors Limited	991,863 1,557,352 590,950 29,599 55,099 180,408 3,829	4,472 2,252,705 1,434,750 577,138 - - -	
		3,409,099	4,269,065	

		Figu 31 December 2021 Taka	ures in '000' Taka 30 June 2021 Taka	
		Така	Така	
12	Other payables			
	Accruals	2,132,451	1,581,957	
	Advance from customers	18,772	241,778	
	Security money received from customers	49,476	49,769	
	Workers' profit participation fund	853,582	742,852	
	Tax and VAT deducted at source	94,152	88,518	
	Employees welfare fund	317,688	292,091	
	Rights share deposit to be refunded	564	564	
	Family day fund	5,807	5,492	
	Non-management staff provident fund	7,274	6,107	
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647	
	Payable for redemption of Zero Coupon Bonds	20,403	20,403	
	Management staff provident fund	16,738	8,930	
	Advertisement and promotional funds	42,051	16,747	
	Development funds	11,283	12,440	
		3,573,890	3,071,296	
12 (a)	Consolidated other payables			
	Accruals	4,632,301	4,443,912	
	Advance from customers	176,824	1,186,756	
	Security money received from customers	103,705	103,129	
	Workers' profit participation fund	1,166,980	1,006,003	
	Management staff provident fund	16,738	8,930	
	Tax and VAT deducted at source	245,414	172,566	
	Employees welfare fund	360,578	312,659	
	Rights share deposit to be refunded	564	564	
	Family day fund	5,807	5,492	
	Non-management staff provident fund	7,274	6,107	
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647	
	Payable for redemption of Zero Coupon Bonds	20,403	20,403	
	Creditors for capital expenditure	7,144	4,553	
	Advertisement and promotional funds	42,051	16,747	
	Development funds	11,283	12,440	
		6,800,713	7,303,909	

$\begin{tabular}{ c c c c c c c } \hline July 2021 & July 2020 & to & t$			Fig For the half	ures in '000' Taka f vear from		
Inter-company sales Inter-company sales <thinter-company sales<="" th=""> Inter-company sales</thinter-company>		Pharmaceuticals Animal health Consumer brands Seeds Fertilizer Animal genetics and others Animal genetics and others () Consolidated revenue Gross sales Inter-company sales Cost of sales Opening stock Purchase Closing stock Manufacturing expenses () Consolidated cost of sales Opening stock Purchase		July 2020		
Taka Taka 13 Revenue 7,379,417 6,316,164 Animal health 2,165,430 2,117,755 Consumer brands 3,429,397 3,776,472 Seeds 720,788 741,977 Fertilizer 1,008,272 573,376 Animal genetics and others 125,043 68,473 13 (a) Consolidated revenue 6 68,473 Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 14 Cost of sales 0 9 Opening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) Opening stock 16,031,441 11,843,754 </th <th></th> <th></th> <th>•</th> <th>•</th>			•	•		
13 Revenue Pharmaceuticals 7,379,417 6,316,164 Animal health 2,165,430 2,117,755 Consumer brands 3,429,397 3,776,472 Seeds 720,788 741,977 Fertilizer 1,008,272 573,376 Animal genetics and others 125,043 68,473 14,828,347 13,594,216 13 (a) Consolidated revenue Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales 0 9,37,378,330 14 Cost of sales (6,068,551 4,817,762 Opening stock 6,685,551 4,817,762 12,378,213 (6,008,824) 16,003,782) 12,378,213 Closing stock (6,063,651) (6,008,824) (6,008,824) 16,003,841 11,843,754 Purchase 7,094,288 6,328,997 1,211,400 1,165,001 Ranufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 </th <th></th> <th></th> <th>December 2021</th> <th>December 2020</th>			December 2021	December 2020		
$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$		Pharmaceuticals Animal health Consumer brands Seeds Fertilizer Animal genetics and others (a) Consolidated revenue Gross sales Inter-company sales Cost of sales Opening stock Purchase Closing stock Manufacturing expenses Opening stock Purchase Closing stock Manufacturing expenses Closing stock Manufacturing expenses	Taka			
Animal health 2,165,430 2,117,755 Consumer brands 3,429,397 3,776,472 Seeds 720,788 719,977 Fertilizer 1,008,272 573,376 Animal genetics and others 125,043 68,473 14,828,347 13,594,216 13 (a) Consolidated revenue Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales 0pening stock 6,685,551 4,817,762 9,005,824) Querchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock 6,685,551 4,817,762 9,005,824) Manufacturing expenses 1,211,400 1,165,001 14 (a) Consolidated cost of sales 0 8,305,688 7,493,998 14 (a) Consolidated cost of sales 0 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010	13	Revenue				
Animal health 2,165,430 2,117,755 Consumer brands 3,429,397 3,776,472 Seeds 720,788 741,977 Fertilizer 1,008,272 573,376 Animal genetics and others 125,043 68,473 14,828,347 13,594,216 13 (a) Consolidated revenue 370,786 Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 14 Cost of sales 0pening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,6963,651) (6,008,824) 16,6008,824) Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales 0pening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 33,137,825 24,717,186 Opening stock 16,031,441 11,843,754 1,137,825 24,717,186 Manuf		Pharmaceuticals	7,379.417	6,316,164		
Consumer brands 3,429,397 3,776,472 Seeds 720,788 741,977 Fertilizer 1,008,272 573,376 Animal genetics and others 125,043 68,473 14,828,347 13,594,216 13 (a) Consolidated revenue Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales 0pening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,6963,651) (6,008,824) 0,608,824) Opening stock 1,04,057,939 12,337,821 1,050,001 Ranufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales 0pening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock 16,031,441 11,843,2754 <td< td=""><td></td><td>Animal health</td><td></td><td></td></td<>		Animal health				
Seeds 720,788 741,977 Fertilizer 1,008,272 573,376 Animal genetics and others 125,043 68,473 14,828,347 13,594,216 13 (a) Consolidated revenue Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales 0 Opening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 12,044,257,939 12,337,821 Closing stock (6,665,651) (6,008,824) Manufacturing expenses 1,211,400 1,165,001 7,094,288 6,328,997 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales 0 Opening stock 16,031,441 11,843,754 9 Purchase 32,116,866 26,695,787 Ging stock (17,010,482) (13,822,355) Opening stock 16,031,441 11		Consumer brands				
Fertilizer 1,008,272 573,376 Animal genetics and others 125,043 68,473 14,828,347 13,594,216 13 (a) Consolidated revenue Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales 7,372,388 7,520,059 Opening stock 6,685,551 4,817,762 Purchase 7,379,391 12,337,821 Closing stock (6,963,651) (6,008,824) Topening stock 16,031,441 11,843,754 Purchase 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales 0 2,116,866 26,695,787 48,148,307 38,539,541 11,843,754 2,4717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 3,1137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353						
Animal genetics and others 125,043 68,473 14,828,347 13,594,216 13 (a) Consolidated revenue Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 14 Cost of sales 37,378,330 14 Cost of sales 0pening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 12,37,821 Closing stock (6,963,651) (6,008,824) 7,094,288 6,328,997 12,317,821 Closing stock 16,031,441 11,843,754 Purchase 3,211,6,866 26,695,787 Purchase 32,116,866 26,695,787 Qpening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 Question stock (17,010,482) (13,822,535) Closing stock 10,137,825 24,717,186 Question stock (17,101,482) (13,822,535) Question straive expenses 30,6329 288,745						
13 (a) Consolidated revenue Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 14 (a) Consolidated cost of sales 7,493,998 14 (a) Consolidated cost of sales 32,116,866 26,695,787 48,148,307 38,595,541 (13,822,355) 13,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 306,329 288,745 288,745 Distribution expenses 378,699 505,887 36,616,599 36,65,99						
Gross sales 46,866,142 38,185,066 Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales 0pening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales 0pening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 38,539,541 Closing stock (17,010,482) (13,822,355) 14 (a) Consolidated cost of sales 31,137,825 24,717,186 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 306,329 288,745 31,61,599 15 Administrative expenses 578,699 505,887 39,55,03 3,616,599		i minimi generies und others				
Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales Opening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) 0 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 14 (a) Consolidated cost of sales 31,137,825 24,717,186 Manufacturing expenses 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599 505,887	13 (a)	Consolidated revenue				
Inter-company sales (1,047,492) (806,736) 45,818,649 37,378,330 14 Cost of sales Opening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) 0 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 14 (a) Consolidated cost of sales 31,137,825 24,717,186 Manufacturing expenses 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599 505,887		Gross sales	46 866 142	38 185 066		
45,818,649 37,378,330 14 Cost of sales Opening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 11,843,754 Closing stock 11,71,225 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 378,699 505,887 Selling expenses 37,378,330 3,616,599						
Opening stock 6,685,551 4,817,762 Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 32,116,866 26,695,787 38,539,541 Closing stock (17,010,482) (13,822,355) Closing stock 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 31 15 Administrative, selling and distribution expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599		inter company sures				
Purchase 7,372,388 7,520,059 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) Closing stock 11,17,825 24,717,186 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 306,329 288,745 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599	14	Cost of sales				
Closing stock 14,057,939 12,337,821 Closing stock (6,963,651) (6,008,824) 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) Closing stock 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 306,329 288,745 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599		Opening stock	6,685,551	4,817,762		
Closing stock (6,963,651) (6,008,824) 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock Closing stock (17,010,482) (13,822,355) 31,137,825 24,717,186 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 306,329 288,745 288,745 Distribution expenses 578,699 505,887 3,935,503 3,616,599		Purchase	7,372,388	7,520,059		
Manufacturing expenses 7,094,288 6,328,997 Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599			14,057,939			
Manufacturing expenses 1,211,400 1,165,001 8,305,688 7,493,998 14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599		Closing stock	(6,963,651)	(6,008,824)		
8,305,688 7,493,998 14 (a) Consolidated cost of sales 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses Administrative expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599						
14 (a) Consolidated cost of sales Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses Administrative expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599		Manufacturing expenses		1,165,001		
Opening stock 16,031,441 11,843,754 Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses Administrative expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599			8,305,688	7,493,998		
Purchase 32,116,866 26,695,787 48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses Administrative expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599	14 (a)	Consolidated cost of sales				
48,148,307 38,539,541 Closing stock (17,010,482) (13,822,355) 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses Administrative expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599		Opening stock	16,031,441	11,843,754		
Closing stock (17,010,482) (13,822,355) 31,137,825 24,717,186 Manufacturing expenses 2,073,528 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses Administrative expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599		Purchase	32,116,866	26,695,787		
Manufacturing expenses 31,137,825 24,717,186 Manufacturing expenses 1,961,867 33,211,353 26,679,053 15 Administrative, selling and distribution expenses Administrative expenses 306,329 288,745 Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599			48,148,307	38,539,541		
Manufacturing expenses2,073,5281,961,86733,211,35326,679,05315Administrative, selling and distribution expensesAdministrative expenses306,329288,745Distribution expenses578,699505,887Selling expenses3,935,5033,616,599		Closing stock	(17,010,482)	(13,822,355)		
33,211,35326,679,05333,211,35326,679,05315Administrative, selling and distribution expensesAdministrative expenses306,329288,745Distribution expenses578,699505,887Selling expenses3,935,5033,616,599			31,137,825	24,717,186		
15Administrative, selling and distribution expensesAdministrative expenses306,329Distribution expenses578,699Selling expenses3,935,5033,935,5033,616,599		Manufacturing expenses	2,073,528	1,961,867		
Administrative expenses306,329288,745Distribution expenses578,699505,887Selling expenses3,935,5033,616,599			33,211,353	26,679,053		
Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599	15	Administrative, selling and distribution expenses				
Distribution expenses 578,699 505,887 Selling expenses 3,935,503 3,616,599		Administrative expenses	306,329	288,745		
Selling expenses 3,935,503 3,616,599		-	578,699	505,887		
		-	3,935,503			
				4,411,231		

		Fig For the half	gures in '000' Taka f year from
		July 2021 to December 2021 Taka	July 2020 to December 2020 Taka
15 (a)	Consolidated operating expenses		
_	Administrative expenses Distribution expenses Selling expenses	1,513,691 1,236,389 6,529,274	1,505,605 993,431 5,683,697
-		9,279,355	8,182,733
16	Reconciliation of net operating cash flow		
	Profit after tax	1,390,014	1,387,628
	 Adjustment for non-cash items and others: Depreciation and amoritisation Provisions Finance cost Tax Expense Contribution to WPPF Lease and other adjustments 	240,059 325,505 202,547 477,393 98,285 83,333	237,725 413,112 180,458 486,782 98,653 76,492
	Changes in:		
	 Inventories Trade and other receivables Advances, deposits and prepayments Trade and other payables, employment benefits 	(256,226) (805,446) 132,986 583,618	(1,068,410) (561,042) (103,406) 704,348
	Cash generated from operating activities	2,472,069	1,852,341
	Paid to WPPF Interest paid Income tax paid Net cash from operating activities	(11,473) (197,483) (286,396) 1,976,717	(12,378) (155,676) (270,237) 1,414,050
16 (a)	Reconciliation of Consolidated net operating cash flow		
	Profit after tax	609,772	160,000
	 Adjustment for non-cash items and others: Depreciation and amoritisation Provisions Share of profit of equity accounted investees Finance cost Tax Expense Contribution to WPPF Lease and other adjustments 	773,940 339,364 (214,349) 1,832,473 1,072,489 184,715 228,211	777,017 459,496 (251,665) 1,793,654 851,076 153,835 214,753

Changes in:		
- Inventories	(926,119)	(2,985,002)
- Trade and other receivables	(1,429,435)	(540,350)
- Advances, deposits and prepayments	161,447	(298,439)
- Trade and other payables, Employment benefits	283,475	14,973
Net cash from operating activities	2,915,983	349,350
Paid to WPPF	(55,168)	(42,647)
Interest paid	(1,606,892)	(1,474,313)
Income tax paid	(847,071)	(758,897)
Net cash from operating activities	406,852	(1,926,507)

17 Consolidated operating segments Please see Annexure A.

18

	For the half	f year from
	July 2021	July 2020
	to December 2021	to December 2020
Consolidated EPS, NAV per share, and NOCFPS		
Weighted average number of ordinary shares (in thousand)	72,577	72,577
Consolidated profit attributable to equity		
holders of the Company (Taka '000)	400,235	201,259
Earnings per share (Taka)	5.51	2.77
Consolidated cash flows from operating activities		
(Taka '000)	406,852	(1,926,507)
Net operating cash flows per share (NOCFPS)	5.61	(26.54)
	31 December 2021	30 June 2021
	Taka	Taka
Consolidated net asset attributable to equity		
holders of the Company (Taka '000)	10,207,375	10,264,844
Net asset value (NAV) per share	140.64	141.43

Reasons for significant deviations: During the six months period ended on 31 Dec 2021, the Group achieved a notable revenue growth which was mainly contributed by the sales growth in some of the business segments as demonstrated in Annexure-A: Consolidated operating segments. The higher growth in consolidated revenue compared to the growth in expenses contributed to the increase in consolidated profit compared to the SPLY. The consequential results of increased consolidated revenue and profit ultimately contributed to improve consolidated EPS and NOCFPS.

19 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A

Consolidated operating segments

Figures in '000' Taka For the half year from July 2021 to December 2021

	Reportable Segment									Total	Unallocated/			
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
	5 250 415	0.165.400	2 271 004	1 024 765	0.004.056	0.007.1.00	6 412 007	1 404 026	2 571 465	2.070.256	010 (00	12 5 62 005	2.256.644	45 010 640
External revenue	7,379,417	2,165,430	3,271,994	1,834,765	9,824,856	2,807,162	6,412,997	1,404,936	3,571,465	3,078,356	810,629	42,562,005	3,256,644	45,818,649
Inter-segment revenue	-	-	411,436	-	14,344	47,561	36,948	21,468	74,582	313,339	-	919,678	127,815	1,047,492
Segment revenue	7,379,417	2,165,430	3,683,430	1,834,765	9,839,201	2,854,723	6,449,945	1,426,403	3,646,047	3,391,695	810,629	43,481,683	3,384,459	46,866,142
Depreciation and amortisation	150,616	13,302	47,785	8,964	37,856	19,209	76,694	34,906	32,618	134,151	175,952	732,052	41,888	773,940
Operating expenses	3,099,304	445,287	1,057,443	305,804	1,270,314	135,234	1,222,297	150,581	322,201	269,582	559,015	8,837,061	442,293	9,279,355
Finance cost / (income)	72,620	45,950	44,600	59,726	151,945	(21,306)	615,992	(43,132)	139,679	232,886	424,545	1,723,504	108,968	1,832,473
Segment profit/(loss) before tax	1,262,730	130,444	(154,720)	276,961	1,056,549	(7,437)	(581,143)	294,392	46,733	(69,486)	(865,742)	1,389,282	292,980	1,682,261
Segment assets at 31 Dec 2021	11,585,039	2,789,438	4,760,760	2,751,689	13,175,235	1,867,928	3,890,934	2,970,186	2,864,082	6,732,860	9,618,994	63,007,144	11,176,261	74,183,405
Segment liabilities at 31 Dec 2021	4,077,166	1,422,511	2,121,633	1,569,338	6,156,299	686,779	17,894,771	1,098,570	4,641,214	6,117,502	14,026,942	59,812,724	2,375,755	62,188,479

For the half year from July 2020 to December 2020

		Reportable segment										Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	6,316,164	2,117,755	3,666,666	1,528,648	5,670,022	2,432,584	6,120,399	937,240	2,907,179	2,773,585	805,770	35,276,011	2,102,319	37,378,330
Inter-segment revenue	-	-	305,055	-	10,800	23,111	28,479	24,460	66,048	249,245	-	707,198	99,538	806,736
Segment revenue	6,316,164	2,117,755	3,971,721	1,528,648	5,680,822	2,455,695	6,148,878	961,699	2,973,228	3,022,830	805,770	35,983,209	2,201,857	38,185,066
Depreciation and amortisation	154,485	12,578	39,014	10,382	32,756	17,423	93,777	25,561	32,061	129,213	174,336	721,587	55,431	777,017
Operating expenses	2,576,856	438,568	1,260,262	263,405	763,630	133,655	1,203,230	126,111	249,011	275,335	595,347	7,885,409	297,325	8,182,733
Finance cost / (income)	59,820	57,730	23,410	65,458	135,895	(22,592)	626,550	(32,818)	148,075	230,237	404,838	1,696,604	97,050	1,793,654
Segment profit/(loss) before tax	1,311,678	165,290	(201,527)	205,219	601,867	41,568	(696,239)	178,772	8,039	57,425	(934,506)	737,587	273,490	1,011,077
Segment assets at 30 June 2021	11,932,171	2,700,827	4,757,239	2,546,825	14,051,260	1,716,688	3,693,664	2,660,555	2,676,007	6,920,779	9,423,781	63,079,796	9,019,860	72,099,655
Segment liabilities at 30 June 2021	3,556,097	1,557,332	1,764,652	1,672,648	8,575,159	511,893	17,077,548	994,856	4,476,547	6,156,294	13,006,408	59,349,435	1,647,169	60,996,604